1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2017-08-07
Target enrollment:
Participant gender:
Summary
This is an open label trial of Anti PD1/MD-3475, Pomalidomide and dexamethasone. The study
will use standard (FDA approved) doses for both pomalidomide and dexamethasone. The
experimental drug Anti PD-1 (MK 3475) given on days 1 and 14.